You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

56 Results
Guidelines and Advice
Status: Archived
ID: 15-15
Sep 2017
Guidelines and Advice
Status: Current
ID: PET 17
Jan 2017
Guidelines and Advice
Status: Current
ID: PET 18
May 2017
Guidelines and Advice
Status: Current
Jun 2017
Guidelines and Advice
Status: Current
Version: 1
Sep 2017
Guidelines and Advice
Status: Current
ID: 26-1
Version: 2
Mar 2017
Guidelines and Advice
Status: Current
ID: GL-C50-31
Mar 2017
Cancer facts
Jun 2017
Regimen
Cancer Type:
Genitourinary, 
Testis
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Adjuvant
Drugs Used:
etoposide,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2017
Statistical Reports
*/ For the most recent data, refer to the Ontario Cancer Screening Performance Report 2023.
May 2017
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • bicalutamide
ODB - General Benefit
  • leuprolide - long-acting formulation
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bicalutamide,
leuprolide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2017
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • triptorelin
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
triptorelin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2017

Pages